Results 11 to 20 of about 15,205 (209)

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study [PDF]

Frontiers in Cardiovascular Medicine, 2021
Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs ...
Swathi Pathadka, Vincent K. C. Yan, Xue Li, Xue Li, Xue Li, Gary Tse, Eric Y. F. Wan, Eric Y. F. Wan, Hayden Lau, Hayden Lau, Wallis C. Y. Lau, Wallis C. Y. Lau, David C. W. Siu, Esther W. Chan, Ian C. K. Wong, Ian C. K. Wong   +15 more
doaj   +6 more sources

Neurohormonal modulation: The new paradigm of pharmacological treatment of heart failure [PDF]

Revista Portuguesa de Cardiologia, 2019
The current paradigm of medical therapy for heart failure with reduced ejection fraction (HFrEF) is triple neurohormonal blockade with an angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB) and a mineralocorticoid receptor antagonist (MRA)
J. Silva-Cardoso, D. Brás, F. Canário-Almeida, A. Andrade, L. Oliveira, F. Pádua, C. Fonseca, N. Bragança, S. Carvalho, R. Soares, J. Ferreira Santos   +10 more
doaj   +3 more sources

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF [PDF]

, 2016
Background: Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse, the latter patients often do not receive treatment with life-saving therapies that might ...
Michael Böhm, Robin Young, Pardeep S. Jhund, Scott D. Solomon, Jianjian Gong, Martin Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor Shi, Karl Swedberg, Michael R. Zile, Milton Packer, John J.V. McMurray   +12 more
openalex   +4 more sources

Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts

Scientific Reports, 2021
Left ventricular remodeling due to pressure overload is associated with poor prognosis. Sacubitril/valsartan is the first-in-class Angiotensin Receptor Neprilysin Inhibitor and has been demonstrated to have superior beneficial effects in the settings of ...
Xiaofei Li, Julie Braza, Ulrike Mende, Gaurav Choudhary, Peng Zhang   +4 more
doaj   +1 more source

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats

Molecules, 2021
The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with cardioprotective properties.
Pema Raj, Karen Sayfee, Mihir Parikh, Liping Yu, Jeffrey Wigle, Thomas Netticadan, Shelley Zieroth   +6 more
doaj   +1 more source

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF).
April F. Mohanty, Emily B. Levitan, Jordan B. King, John A. Dodson, Orly Vardeny, James Cook, Jennifer S. Herrick, Tao He, Olga V. Patterson, Patrick R. Alba, Patricia A. Russo, Engels N. Obi, Michelle E. Choi, James C. Fang, Adam P. Bress   +14 more
doaj   +1 more source

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Cardiovascular Diabetology, 2022
Background Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial.
Magnus O. Wijkman, Brian Claggett, Muthiah Vaduganathan, Jonathan W. Cunningham, Rasmus Rørth, Alice Jackson, Milton Packer, Michael Zile, Jean Rouleau, Karl Swedberg, Martin Lefkowitz, Sanjiv J. Shah, Marc A. Pfeffer, John J. V. McMurray, Scott D. Solomon   +14 more
doaj   +1 more source

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials

Frontiers in Public Health, 2022
BackgroundSacubitril-valsartan was recommended for heart failure (HF) and proven cost-effective in HF. Recently, sacubitril-valsartan has been recommended to treat hypertension by the Chinese expert consensus. The cost utility of sacubitril-valsartan for
Yake Lou, Ying Yu, Ying Yu, Jinxing Liu, Jing Huang   +4 more
doaj   +1 more source

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction

Frontiers in Cardiovascular Medicine, 2023
IntroductionIn 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from ...
Pei Yang, Pei Yang, Xiaokang Li, Lijin Wang, Xinlei Wu, Chiyao Wang, Tian Li, Haiyan Wang   +7 more
doaj   +1 more source

Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure [PDF]

, 2018
Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Claggett, Brian, Damman, Kevin, Desai, Akshay S., Gori, Mauro, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Prescott, Margaret F., Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +14 more
core   +9 more sources